COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Not yet submitted
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility Trial of the Venous Window Needle Guide - Surgical for Patients Who Have Difficult-to-Cannulate Native Arterial-Venous (A-V) Fistula for Hemodialysis
Scientific title
A feasibility study of 7 chronic hemodialysis patients with difficult-to-access fistula undergoing implantation of the Venous Window Needle Guide to facilitate fistula access and development of buttonhole cannulation site.
Secondary ID [1] 251803 0
Universal Trial Number (UTN)
Trial acronym
Vital Access Needle Guide
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Difficult to cannulate AV fistula for chronic hemodialysis. 256807 0
Condition category
Condition code
Renal and Urogenital 256957 256957 0 0
Kidney disease

Study type
Description of intervention(s) / exposure
The Venous Window Needle Guide is implanted onto the surface of an AV fistula by a vascular surgeon using a surgical technique. The skin will be closed over the implant. The duration of the surgical procedure will be approximately 30 minutes. Access of the AV fistula with a fistula needlle through the implant will be begin approximately three weeks following the intervention. Patients will be observed for six months post intervention.
Intervention code [1] 256012 0
Treatment: Devices
Intervention code [2] 256541 0
Treatment: Surgery
Comparator / control treatment
Patients will have both intervention and non-intervention A-V fistula access sites. The non-intervention access site will act as the comparator access site to the intervention access site.
Control group

Primary outcome [1] 257837 0
AV fistula access through Venous Window Needle Guide utilizing buttonhole cannulation technique resulting in hemodialysis session within normal pressure and flow parameters.
Timepoint [1] 257837 0
3 months post intervention
Secondary outcome [1] 263251 0
Successful placement of study device, defined as placement of the Venous Window Needle Guide with proper attachment, alignment and palpability on a native A-V fistula in an upper extremity
Timepoint [1] 263251 0
At time of intervention procedure.
Secondary outcome [2] 263252 0
Successful cannulation (blood return) of AV fistula through the Venous Window Needle Guide with sharp fistulae needle.
Timepoint [2] 263252 0
3 - 5 weeks post intervention
Secondary outcome [3] 263253 0
Successful cannulation (blood return) of AV fistula through Venous Window Needle Guide with blunt fistula needle.
Timepoint [3] 263253 0
Within 3 months post intervention

Key inclusion criteria
1. Patient is currently successfully dialysed via existing A-V fistula. 2. AV Fistula diameter is at least 5mm at the site of device attachment. 3. Buttonhole cannulation technique is appropriate. 4. AV Fistula is or may be difficult to palpate or cannulate (short length, non-palpable, limited fistula life expectancy, etc.). 5. AV Fistula does not have flow abnormalities
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Patient younger than 18 years of age
2. Skin infection at potential implant sites.
3. Pregnancy
4. Known bleeding disorder, e.g., low platelet count (<50,000), hypercoagulable state, e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating Lupus anticoagulant; current, active heparin-induced thrombocytopenia; Protein C or S deficiency; or history of recurrent deep vein thrombosis not related to AV access.
5. Active malignancy, e.g., condition either being treated or considered untreatable
6. Active systemic infection, e.g., condition either being treated or considered untreatable
7. Uncontrolled major symptomatic medical problem, e.g., undiagnosed severe pain, metabolic disturbance, fever, etc.
8. Likelihood of poor compliance to required dialysis protocol, e.g., history of poor attendance to required clinic sessions or non-compliance to medication
9. Mental incapacity; inability to understand treatment instructions
10. Currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 2493 0
New Zealand
State/province [1] 2493 0

Funding & Sponsors
Funding source category [1] 256514 0
Commercial sector/Industry
Name [1] 256514 0
Vital Access, Corp.
Address [1] 256514 0
2302 South Presidents Drive, Suite C
Salt Lake City, Utah 84120
Country [1] 256514 0
United States of America
Primary sponsor type
Commercial sector/Industry
Vital Access, Corp.
2302 South Presidents Drive, Suite C
Salt Lake City, Utah 84120
United States of America
Secondary sponsor category [1] 255823 0
Name [1] 255823 0
Address [1] 255823 0
Country [1] 255823 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 258559 0
Ethics committee address [1] 258559 0
Ethics committee country [1] 258559 0
Date submitted for ethics approval [1] 258559 0
Approval date [1] 258559 0
Ethics approval number [1] 258559 0

Brief summary
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 30837 0
Address 30837 0
Country 30837 0
Phone 30837 0
Fax 30837 0
Email 30837 0
Contact person for public queries
Name 14084 0
Mark Crawford
Address 14084 0
2302 South Presidents Drive, Suite C
Salt Lake City, Utah 84120
Country 14084 0
United States of America
Phone 14084 0
+1 801-433-9390
Fax 14084 0
+1 801-433-9391
Email 14084 0
Contact person for scientific queries
Name 5012 0
Mark Crawford
Address 5012 0
2302 South Presidents Drive, Suite C
Salt Lake City, Utah 84120
Country 5012 0
United States of America
Phone 5012 0
+1 801-433-9390
Fax 5012 0
+1 801-433-9391
Email 5012 0

No information has been provided regarding IPD availability
Summary results
No Results